Reference only. Testing guidance shown is derived from published clinical guidelines and regulatory sources. It does not constitute a clinical recommendation for any individual patient. Payer coverage information is a general summary and may not reflect current policy or individual benefit design. Full disclaimer
B-Cell LymphomasICD-10: C83.3
Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL is the most common aggressive B-cell lymphoma (~25% of NHL). Cell-of-origin (GCB vs. ABC/non-GCB) is prognostically critical. MYC/BCL2 double-hit (HGBL) requires intensified induction (DA-EPOCH-R vs. R-CHOP or pola-R-CHP).
WHO Classification
Ann Arbor / Lugano 2014Ann Arbor staging system (modified by Lugano 2014 classification) for lymphomas. Stages I–IV based on number of lymph node regions involved and presence of extranodal disease.
Stage IInvolvement of a single lymph node region (I) or single extralymphatic organ/site (IE). Limited disease — often treated with combined modality or abbreviated systemic therapy.Stage IIInvolvement of two or more lymph node regions on the same side of the diaphragm (II), or localized extralymphatic involvement + regional nodes on the same side (IIE).Stage IIIInvolvement of lymph node regions on both sides of the diaphragm (III), with or without spleen (IIIS) or extralymphatic site (IIIE). Advanced disease.Stage IVDiffuse or disseminated involvement of one or more extralymphatic organs. Bone marrow involvement = Stage IV by definition.
Recommendations reflect published guidelines as of their listed evidence dates. Staging categories without recommendations may not yet be included in this reference. Always consult current guidelines and institutional protocols.